Skip to main content

Table 1 Annual absolute percentage change in femoral neck BMD: observed data and scenarios for extrapolated

From: What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia

Year

On treatmenta

Off treatment

Observedb

Extrapolatedc

Observedb

Extrapolation scenariosc

Base case

Sensitivity scenario

Base case

Sensitivity scenario

1

2.82

  

0.14

  

2

1.22

  

−0.38

  

3

0.94

  

−0.69

  

4

0.98

   

−0.53

−0.69

5

0.34

   

−0.53

−0.69

6

 

0.66

0.87

 

−0.53

−0.69

7

 

0.66

0.87

 

−0.53

−0.69

8

 

0.66

0.87

 

−0.53

−0.69

9

 

0.66

0.87

 

−0.53

−0.69

10

 

0.66

0.87

 

−0.53

−0.69

  1. aAnnual percentage changes in BMD assumed to be equal for patients remaining on treatment with either denosumab or alendronate
  2. bRef. [6]
  3. cBase case extrapolations equal to average effects in last two years, sensitivity analyses based on average effect in last three years on treatment and in last year off treatment
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us